Relapsed Or Refractory Mantle Cell Lymphoma Archives - DelveInsight

Relapsed Or Refractory Mantle Cell Lymphoma

pharma-news
Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL

Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1Primary Hyperoxaluria Type 1 (PH1) is a rare ...


Pharma News
Good news for Kite’s KTE-X19, and Aquestive’s Libervant; and a commercialization deal between ReF...

FDA has accepted Biological License Application submitted by Kite for its CAR-T cell therapy- KTE-X19, for relapsed or refractory mantle cell lymphoma (MCL)The drug- KTE-X19, which is an inves...


Editor's Pick
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies ...

Progress is driven by innovation. When it comes to developing novel medications and the...

Changing Dynamics of HIV-1 Treatment Market

The HIV-1 treatment market for naïve and experienced patients is evolving consistently....

Which Countries Top the Chart in Global Pharmaceutical Market?

The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...

von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...

Analyzing the Key Companies and the Emerging Gene Therapy in the Dermatology ...

Advances in genetics research have sparked a surge in interest in gene therapy in derma...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.